Pasritamig

DRUG4 trials

Conditions

Metastatic Castration-resistant Prostate NeoplasmsMetastatic Castration-resistant Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate CancerProstatic NeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

RecruitingNCT05818683

Janssen Research & Development, LLCMetastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

Start: 2023-04-26End: 2028-05-23Target: 300Updated: 2026-08-28

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

RecruitingNCT07319871

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2026-01-14End: 2027-04-30Target: 40Updated: 2026-08-28

Phase 3

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

RecruitingNCT07164443

Janssen Research & Development, LLCMetastatic Castration-resistant Prostatic Neoplasms

Start: 2025-09-02End: 2028-08-18Target: 1203Updated: 2026-08-28

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT07225946

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2025-12-19End: 2029-07-20Target: 800Updated: 2026-08-28

Related Papers

A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2026-05-28